title: Severe acute respiratory syndrome. The Mount Sinai experience.
authors.affiliation: Mount Sinai Hospital, Toronto, Ontario.
authors.forename: Patricia
authors.initials: P
authors.lastname: Hynes-Gay
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Bennett
authors.forename: Ahilya
authors.initials: A
authors.lastname: Sarjoo-Devries
authors.forename: Helen
authors.initials: H
authors.lastname: Jones
authors.forename: Allison
authors.initials: A
authors.lastname: McGeer
mesh_terms: D000328:Adult; D000399:Air Pressure; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D002170:Canada; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D017053:Infection Control / Q000592:standards*; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage; D015242:Ofloxacin / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage; D045473:Severe acute respiratory syndrome-related coronavirus; D045169:Severe Acute Respiratory Syndrome / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D000998:Antiviral Agents; D005938:Glucocorticoids; D012254:Ribavirin; D008776:Methylprednisolone Hemisuccinate; D015242:Ofloxacin